ライフサイエンスコーパス: desipramine

1 hypersensitivity with neuromodulators (e.g., desipramine).

2 symptoms compared with patients assigned to desipramine.

3 symptoms (> or =40% reduction) compared with desipramine.

4 tentiated by the neuronal uptake-1 inhibitor desipramine.

5 SERT for the antidepressants paroxetine and desipramine.

6 (n = 14) were treated on an open basis with desipramine.

7 ix months of a clinically determined dose of desipramine.

8 re blocked by cocaine and the antidepressant desipramine.

9 lacebo-treated alcoholics and can respond to desipramine.

10 ntidepressants clomipramine, paroxetine, and desipramine.

11 3 tracers was inhibited by pretreatment with desipramine.

12 ine, to the norepinephrine uptake inhibitor, desipramine.

13 complex with leucine and the antidepressant desipramine.

14 broblasts) with the tricyclic antidepressant desipramine (0.1-10 microM) in the presence or absence o

15 transporter (NET) inhibitors citalopram and desipramine (1 mg kg(-1) ).

16 ment with the tricyclic antidepressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake

17 antidepressants fluoxetine (5 mg/kg/day) and desipramine (10 mg/kg/day), and 3) forced swim test beha

18 erfusion was attenuated approximately 80% by desipramine (10 nmol/L) and 70% by 5-(N-ethyl-N-isopropy

19 selective norepinephrine uptake-1 inhibitor desipramine (2 mg/kg intravenously; n = 4), or saline co

20 Desipramine (2, 4, 8 micrograms/side), nisoxetine (2, 4,

21 Administration of desipramine (20 mg/kg, i.p.) 30 min prior to 6-OHDA inje

22 ligature-induced periodontitis treated with desipramine (20 mg/kg/d in vehicle).

23 tested the hypothesis that administration of desipramine 200 mg prevents the state-related reduction

24 eks of the noradrenaline re-uptake inhibitor desipramine (5 mg/kg).

25 ceive 8 weeks of double-blind treatment with desipramine (50-200 mg/day) or fluoxetine (10-40 mg/day)

26 The antidepressants used were: desipramine (8 mg/kg, i.p., tricyclic), fluoxetine (8 mg

27 ertraline and fluoxetine) or norepinephrine (desipramine), a monoamine oxidase inhibitor (tranylcypro

28 norepinephrine selective reuptake inhibitor (desipramine), a serotonin selective reuptake inhibitor (

29 ermore, both palmitoyldihydrosphingosine and desipramine, a chemically and mechanically unrelated aci

30 The amphiphilic compound desipramine, a frequently employed inhibitor of acid sph

31 when 6-OHDA was injected in combination with desipramine, a noradrenaline (NA) reuptake inhibitor, pr

32 We report that both cocaine and desipramine, a potent NET inhibitor, failed to change DA

33 ith each tracer after oral administration of desipramine, a selective neuronal transport blocker.

34 tonin reuptake inhibitor, and active control desipramine, a selective norepinephrine reuptake inhibit

35 otonin reuptake inhibitor fluoxetine but not desipramine, a selective norepinephrine reuptake inhibit

36 Desipramine abolished the normal reduction of geniogloss

37 al treatment (omeprazole plus baclofen, with desipramine added depending on symptoms), or control med

38 Desipramine administration downregulated mRNA expression

39 Desipramine administration reduced alveolar bone loss as

40 n DAT-KO mice, whereas local PFC infusion of desipramine alone produced this same effect.

41 Neither 6-OHDA nor desipramine altered striatal PDE4A or PDE4B isozymes.

42 Ionization energies of imipramine, desipramine, amitriptyline, and clomipramine are predict

43 four tricyclic antidepressants: imipramine, desipramine, amitriptyline, and clomipramine.

44 of forebrain BDNF attenuates the actions of desipramine, an antidepressant, in the forced swim test,

45 n affinity for dopamine, a NET substrate, or desipramine, an inhibitor, at the expense of affinity fo

46 s known to inhibit mammalian ASM activities, desipramine and clomipramine, markedly extend the lifesp

47 nt with the neuronal amine-uptake inhibitors desipramine and cocaine, the alpha 1-adrenoceptor agonis

48 in the NAc increases the efficacy of the TCA desipramine and dramatically accelerates its onset of ac

49 the functionalization of the antidepressants desipramine and fluoxetine and the preparation of an aza

50 uation, employing well-known antidepressants desipramine and fluoxetine as test compounds in dog and

51 of C6 glioma cells with the antidepressants desipramine and fluoxetine increases the Triton X-100 so

52 repeated treatment with the antidepressants desipramine and fluoxetine or the PDE4 inhibitor rolipra

53 After initial medication with desipramine and follow-up until response, patients under

54 On using desipramine and imipramine as "arbitrarily selected stan

55 nhibitors of acid sphingomyelinase (ASMase), desipramine and imipramine, attenuated ATP-induced TF de

56 Desipramine and imipramine, inhibitors of acid sphingomy

57 The antidepressants fluoxetine, desipramine and ketamine increased PKMzeta expression in

58 and 6 were increased by the antidepressants desipramine and mirtazapine.

59 pable of causing marked elevations in plasma desipramine and nortriptyline concentrations.

60 ne reinstated the behavioral effects of both desipramine and paroxetine in Dbh(-/-) mice, thus demons

61 gnificant differences between the adjunctive desipramine and placebo groups in obsessive-compulsive o

62 tatistically significant differences between desipramine and placebo in heart rate and blood pressure

63 on of ADHD symptoms between adults receiving desipramine and placebo.

64 more improved with sertraline compared with desipramine and placebo; the factors for mood (P<.001) a

65 ssants, including the NE reuptake inhibitors desipramine and reboxetine, the monoamine oxidase inhibi

66 jection, all three drugs tested: fluoxetine, desipramine and TCP decreased total BDNF mRNA (exon V) a

67 he P450 biotransformation of imipramine into desipramine and to determine the IC50 value of a chemica

68 e interaction of an antidepressant molecule, desipramine, and its location in the membrane.

69 ble for increased sensitivity to imipramine, desipramine, and nortriptyline.

70 s, apical uptake was inhibited by verapamil, desipramine, and quinidine, but not by MPP+ (1-methyl-4-

71 Long-term maintenance treatment with desipramine appeared to be effective in the prevention o

72 his study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.

73 e, we identify the SLC competitive inhibitor desipramine as protective against DIC.

74 placebo-controlled, parallel-design study of desipramine at a target daily dose of 200 mg in 41 adult

75 nally, the acidic sphingomyelinase inhibitor desipramine attenuated HDACI/perifosine-mediated ceramid

76 B variant in hypothalamus; administration of desipramine attenuated the 6-OHDA-induced down-regulatio

77 Pretreatment of rats with desipramine attenuated the 6-OHDA-induced down-regulatio

78 rget these pathways and found that Ambroxol, Desipramine, Azoramide, and Genistein alleviate neurodeg

79 Importantly, desipramine belongs to a group of tricyclic antidepressa

80 he kinetics of cocaine, methylphenidate, and desipramine binding to SERT and DAT.

81 on human SERT and DAT indicate that both the desipramine-binding site and its inhibition mechanism ar

82 Desipramine binds at the inner end of the extracellular

83 Desipramine blocked 5,7-DHT-induced norepinephrine (NE)

84 ts indicate that, as previously reported for desipramine, both amitriptyline and fluoxetine increase

85 n with desipramine pretreatment, a 1.5 mg/kg desipramine chase administered 10 min after tracer injec

86 Additionally, a desipramine chase did not change the cardiac (123)I-MIBG

87 A desipramine chase increased (11)C-hydroxyephedrine washo

88 d heart-to-mediastinum ratio, 1.99 +/- 0.12 (desipramine chase) vs. 2.05 +/- 0.16 (controls), not sta

89 Amitriptyline, nortriptyline, desipramine, clomipramine, dothiepin, and sertraline wer

90 tidepressants: amitriptyline, nortriptyline, desipramine, clomipramine, doxepin, dothiepin, fluoxetin

91 as sensitive to the lysosomotropic inhibitor desipramine, co-fractionated with lysosomes, and migrate

92 airway collapsibility was also reduced with desipramine compared with placebo (-10.0 cm H2O [-15.2 t

93 phasic genioglossus activity was higher with desipramine compared with placebo.

94 repinephrine transporter (NET) blockade with desipramine confirmed specific neural uptake of (18)F-LM

95 Desipramine decreased norepinephrine uptake to near maxi

96 the monkey with the selective NET inhibitor, desipramine, decreased the specific binding for both [(1

97 We also found that the antidepressant desipramine decreases these neural and behavioral effect

98 al therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patien

99 We hypothesized that desipramine (DES), which targets norepinephrine (NE), ma

100 significantly more effective than placebo or desipramine; desipramine was not better than placebo (F2

101 betaA expression, but fluoxetine as well as desipramine did increase Smad2 phosphorylation in the fr

102 Whereas desipramine did not by itself elicit circulating HSPCs,

103 norepinephrine transporter (NET) inhibitor, desipramine, did not adversely affect adult behavior, su

104 Rats pretreated with desipramine (DMI) (to prevent norepinephrine depletion)

105 and the norepinephrine transporter inhibitor desipramine (DMI) 10 mg/kg IP to raise MPFC DA levels wi

106 r to those observed in WT mice after chronic desipramine (DMI) administration.

107 to study the effects of two antidepressants, desipramine (DMI) and fluoxetine (FLX), in behavioral, e

108 Zimelidine (ZMI) and desipramine (DMI) are monoamine uptake inhibitors which

109 Prolonged treatment with the antidepressant desipramine (DMI) decreased the expression of both trans

110 Desipramine (DMI) is an antidepressant classically chara

111 healthy male Wistar rats at baseline, after desipramine (DMI) pretreatment (DMI block), and with DMI

112 essant and norepinephrine reuptake inhibitor desipramine (DMI) strongly suppressed REM sleep in rats

113 e establish that both subchronic and chronic desipramine (DMI) treatments upregulate hypothalamic ICE

114 Therefore, we hypothesized that desipramine (DMI), a NET antagonist, could affect the se

115 Here, we demonstrate that desipramine (DMI), a norepinephrine reuptake inhibitor t

116 Tricyclic antidepressants (TCAs), such as desipramine (DMI), are effective at managing neuropathic

117 ith the norepinephrine transporter inhibitor desipramine (DMI), each of these quantitative measures d

118 ose or long-term (3 weeks) administration of desipramine (DMI), fluoxetine (FLU), and mianserin (MIA)

119 selective norepinephrine reuptake inhibitor desipramine (DMI), or the monoamine oxidase inhibitor ph

120 by determining the effect on cell binding of desipramine (DMI), ouabain, norepinephrine (NE), unlabel

121 Tricyclic antidepressants (TCAs), such as desipramine (DMI), which block norepinephrine transporte

122 tyrosine administration would potentiate the desipramine (DMI)-induced elevation of medial prefrontal

123 inephrine neuronal transporter blockade with desipramine (DMI).

124 er intravenous infusion of the NET inhibitor desipramine (DMI).

125 studied: (Group 1) control; (Group 2) 100 nM desipramine (DMI); (Group 3) 0.8 microM SKF550; (Group 4

126 , a selective serotonin uptake inhibitor) or desipramine (DMI, a selective noradrenaline uptake inhib

127 Five desipramine dose levels were used to establish a range o

128 Further investigations revealed that desipramine down-regulated acid ceramidase (AC), but not

129 of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipr

130 e of depression in patients who responded to desipramine during the acute and continuation phases.

131 RI) and a norepinephrine reuptake inhibitor, desipramine, effectively reduces obsessive-compulsive sy

132 reveal that the NE transporter (NET) blocker desipramine elevates both norepinephrine (NE) and dopami

133 tine and the norepinephrine uptake inhibitor desipramine failed to reverse the effects of TBZ, and hi

134 Compared with desipramine, fluoxetine treatment showed a more rapid re

135 ment of initial antidepressant prescription (desipramine, fluoxetine, or imipramine).

136 a continuation phase of open treatment with desipramine for 16 weeks.

137 Treatment with desipramine for 24-96 hr had no effect on the expression

138 that the selectivity of methylphenidate and desipramine for DAT and SERT, respectively, can be accou

139 primarily norepinephrine reuptake inhibitor desipramine for patients with concurrent OCD and MDD.

140 tine did not show statistical superiority to desipramine for the treatment of PTSD symptoms.

141 for the placebo group and 11% for the active desipramine group (chi 2 = 8.1, P = .004).

142 was significantly reduced in the ligature + desipramine group (P < 0.05), whereas gingival collagen

143 e sertraline group, 18 subjects (36%) in the desipramine group, and 16 subjects (29%) in the placebo

144 e and was characteristic of binding to NETs (desipramine > imipramine > citalopram).

145 myelin levels were not altered by 4-HPR, and desipramine had no effect on ceramide level, suggesting

146 moval of 5-HT but not noradrenaline, whereas desipramine had the reverse action.

147 ition, an acidic sphingomyelinase inhibitor, desipramine, had no effect on TNF-alpha/CHX-induced cell

148 Because the tricyclic anti-depressant desipramine has been found to be effective in treating A

149 o-controlled trial evaluated the efficacy of desipramine hydrochloride (0 or 150 mg/d) plus buprenorp

150 t the results of a long-term study comparing desipramine hydrochloride and placebo for maintenance th

151 mg daily, augmented by lithium carbonate or desipramine hydrochloride if necessary; others received

152 f the noradrenergic tricyclic antidepressant desipramine hydrochloride in the treatment of children a

153 were randomized to sertraline hydrochloride, desipramine hydrochloride, or placebo for 3 months of do

154 Importantly, desipramine, imipramine, and a third ASMase inhibitor, S

155 y measuring the inhibition of its binding by desipramine, imipramine, or citalopram.

156 standard solutions as well as imipramine and desipramine in fortified human plasma samples.

157 d by all drugs tested, with the exception of desipramine in hippocampus.

158 a, we investigated the NE reuptake inhibitor desipramine in HSPC mobilization.

159 Clomipramine was also superior to desipramine in improving functional disability.

160 Clomipramine was superior to desipramine in the acute treatment of body dysmorphic di

161 Clomipramine is more effective than desipramine in the treatment of body dysmorphic disorder

162 I (sertraline) and a non-SRI antidepressant (desipramine) in the treatment of OCD with concurrent MDD

163 Regardless of sex or opioid medication, desipramine increased opioid and cocaine abstinence more

164 nation of two entirely different mechanisms; desipramine increases hERG endocytosis and degradation a

165 ondary dendrites in CA1, with fluoxetine and desipramine increasing the number of secondary dendrites

166 lated net uptake rate constants K(i) tracked desipramine-induced reductions of available NET in a dos

167 us oocytes accumulate 5HT, and paroxetine or desipramine inhibit this uptake.

168 Desipramine inhibition (DMI) of uptake-1 resulted in a s

169 Here, we have studied in detail how desipramine inhibits hERG surface expression.

170 Desipramine is a tricyclic antidepressant with immune-mo

171 ren and adolescents with ADHD, indicate that desipramine is effective in the treatment of ADHD in adu

172 Desipramine may be a useful adjunctive medication in fac

173 ness, helplessness, and hopelessness, in the desipramine-mazindol but not in the fluoxetine-sertralin

174 Treatment with desipramine (mean total daily dose, 3.4 mg/kg per day) w

175 valuated by in vivo inhibition of the NET by desipramine (n = 6).

176 h either norepinephrine reuptake inhibitors (desipramine [n = 7] or mazindol [n = 2]) or serotonin re

177 : paroxetine+naltrexone; paroxetine+placebo; desipramine+naltrexone; desipramine+placebo.

178 c administration of the antidepressant drugs desipramine, nortryptiline and paroxetine (PAR) (10 mg/k

179 The effect of desipramine on doxorubicin cytotoxicity was also investi

180 Systemic administration of desipramine or fluoxetine inhibits hyperactivity in DAT-

181 In a double-blind study, desipramine or placebo was added for 6 or 10 weeks to th

182 norepinephrine-specific re-uptake inhibitor (desipramine), or saline and killed after 24 h.

183 Desipramine- or fluoxetine-treated cells show a more cen

184 activity was lower in the group treated with desipramine (P < 0.05).

185 bstinent significantly longer when receiving desipramine (P=.03).

186 Desipramine partially attenuated the 6-OHDA-mediated dec

187 pendent manner (IC50 = 0.068 +/- 0.010 mg of desipramine per kilogram).

188 oncentration (IC50) of 0.087 +/- 0.012 mg of desipramine per kilogram.

189 paroxetine+placebo; desipramine+naltrexone; desipramine+placebo.

190 Higher desipramine plasma levels were associated with greater o

191 Desipramine plasma levels were determined at weeks 4 and

192 Desipramine plasma levels were higher in women than in m

193 Desipramine pretreatment markedly reduced (> 60%) myocar

194 der norepinephrine transport inhibition with desipramine pretreatment, a 1.5 mg/kg desipramine chase

195 re partially normalized to control values by desipramine pretreatment.

196 ere was preserved (18)F-LMI1195 uptake after desipramine pretreatment.

197 By directly locking the gate, desipramine prevents conformational changes and blocks s

198 dontitis treated with vehicle; 3) ligature + desipramine: rats with ligature-induced periodontitis tr

199 Desipramine reduces the state-related drop in tonic geni

200 eatment with norbinaltorphimine, even though desipramine remained effective.

201 gle dose of 5 and 10 mg/kg for midazolam and desipramine, respectively.

202 on of the antidepressant drugs fluoxetine or desipramine restores learning in mice exposed to the abe

203 Fluoxetine and desipramine reversed lower, but not higher, stress-induc

204 ccumulation is Na(+)-, Cl(-)-, cocaine-, and desipramine-sensitive and temperature-dependent, and tha

205 e in MENX mut/mut rats could be inhibited by desipramine, shown by biodistribution studies (0.06 +/-

206 Desipramine significantly reduced core symptoms of ADHD

207 Likewise, desipramine significantly reduced tic symptoms (Yale Glo

208 e-effect curves were generated with cocaine, desipramine, SKF-38393, quinpirole, SCH-23390, and sulpi

209 cantly inhibited by phenoxybenzamine but not desipramine, suggesting (18)F-LMI1195 is a substrate for

210 the acid sphingomyelinase-inactivating drug, desipramine, synergize to reverse susceptibility, sugges

211 More patients receiving desipramine than sertraline discontinued treatment becau

212 gs (haloperidol, raclopride, sertraline, and desipramine) that lack reinforcing or sensitizing proper

213 lyzed following the normal administration of desipramine to a volunteer, and the parent drug was dete

214 and abdomen, with or without treatment with desipramine to block sympathoneural uptake of catecholam

215 Use of desipramine to reduce relapse in nondepressed alcoholics

216 treatment with paroxetine (to 60 mg/day) or desipramine (to 30 mg/day) in a 3-to-1 ratio, respective

217 Hamilton Depression scores of desipramine-treated depressed alcoholics decreased signi

218 Desipramine-treated depressed patients were more satisfi

219 Within the desipramine-treated group, there were clinically and sta

220 ct, predefined criteria for response, 68% of desipramine-treated subjects and no subjects in the plac

221 change in the distribution of Goalpha after desipramine treatment and the antipsychotic drug chlorpr

222 compared the effectiveness of fluoxetine and desipramine treatment in a prospective double-blind phar

223 ed patients then were randomized to continue desipramine treatment or tapered to placebo treatment fo

224 Desipramine treatment was associated with decreased 6-(1

225 Compared with desipramine treatment, fluoxetine treatment was associat

226 ine or S1P rescued PGE(2) biosynthesis after desipramine treatment.

227 kers such as bongkrekic acid, Nortriptyline, Desipramine, Trifluoperazine, and Maprotiline.

228 t with either sertraline (up to 200 mg/d) or desipramine (up to 300 mg/d) over 12 weeks.

229 he ADHD response rate was robust (71% vs 0%; desipramine vs placebo, P<.001).

230 ic response rate was substantial (58% vs 5%; desipramine vs placebo, P<.001).

231 Desipramine was found to (i) induce GR translocation fro

232 Response to desipramine was independent of dose, level of impairment

233 However, the action of desipramine was independent of its action on ASMase, sin

234 more effective than placebo or desipramine; desipramine was not better than placebo (F2,163 = 12.47,

235 However, desipramine was superior to paroxetine with respect to s

236 Desipramine was titrated weekly up to 3.5 mg/kg per day.

237 Treatment with desipramine was well tolerated and was associated with r

238 sant (fluoxetine) was employed if the first (desipramine) was either ineffective or poorly tolerated,

239 Furthermore, clomipramine, paroxetine, and desipramine were able to induce degranulation of human s

240 analyses of fortified samples of imipramine desipramine were measured relative to their correspondin